dc.contributor.author | Allen, Claire | |
dc.date.accessioned | 2020-03-24T18:35:22Z | |
dc.date.available | 2020-03-24T18:35:22Z | |
dc.date.issued | 2020-03-18 | |
dc.identifier.uri | https://www.evidenceaid.org/extracorporeal-membrane-oxygenation-ecmo-for-patients-with-acute-respiratory-failure-uncertain-if-it-is-better-or-worse-than-conventional-lung-support/ | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/773 | |
dc.description.abstract | What is this? Some patients with COVID-19 will become critically ill and need help with their breathing. Extracorporeal membrane oxygenation (ECMO) is a form of life support that targets the heart and lungs and which might be used for them. In this Cochrane systematic review, the authors searched for randomized and quasi-randomized trials testing the use of ECMO for acute respiratory failure. They did not restrict by language or location of publication and did their searches in August 2014. They identified 4 randomized trials which compared ECMO versus conventional lung support (389 participants). | en_US |
dc.language | English | en_US |
dc.subject | Extracorporeal Membrane Oxygenation | en_US |
dc.subject | Lung Diseases | en_US |
dc.subject | Respiratory Distress | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Infectious Diseases | en_US |
dc.title | Extracorporeal membrane oxygenation (ECMO) for patients with acute respiratory failure: Uncertain if it is better or worse than conventional lung support | en_US |
eihealth.country | Others | en_US |
eihealth.category | Clinical characterization and management | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
dc.relation.ispartofjournal | Evidence Aid | en_US |